Member Info for B2HS2L

I'd like to get a feel for posters views on the following question please:

Is part of the reason that the healthcare partner is doing business with TRX, because it intends to make a future investment in the company?

How much sense does that make when you re-read the last RNS:

Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group" or "Company"), a leading regenerative medicine company, is pleased to announce that it has entered a new strategic collaboration for white label manufacturing with a leading top 10 global healthcare company bringing to market a newly developed product line.

The manufacturing agreement follows collaboration between the R&D teams of both companies to develop a new product using one of the Group's proprietary technology platforms to address orthopaedic soft tissue repairs. Processing for the product has begun, and initial orders have been received. Over the next two years, it is expected that the product will make a material contribution to the Group's top line revenue growth. This new product line is complimentary to the other soft tissue products processed at the San Antonio facility, and due to operational efficiencies implemented, it is not expected that there will be any impact on the current processing levels of other product lines.

I don't think it can have invested already because if it had, then an RNS stating the nature of the investment would be necessary.

Was it not the Abbot's Antibody Test that was found to be faulty in tests within the white house recently?
A bad test is worse than no test etc, so if this is the test found wanting in the white house, save your money.

wfc61, - I posted this finding recently, seems applicable to your discussion:

https://www.express.co.uk/news/world/1277976/Germany-coronavirus-news-covid-19-cases-study-update?int_source=traffic.outbrain&int_medium=traffic.outbrain&int_term=traffic.outbrain&int_content=traffic.outbrain&int_campaign=traffic.outbrain

Not sure if this Express article has been posted before.
From May 6th, it points to a large number of people in Germany who are unaware they are carrying / distributing
the Covid 19 virus, because they have no symptoms.

"The team from the University of Bonn said there was potential for huge amounts of carriers not to have displayed any symptoms but still pose an infection risk to others.

Their report comes as Germany prepares to ease its lockdown with museums, hairdressers, churches and more car factories beginning to reopen.

It found one in five of those who had been infected with coronavirus reported no symptoms.

The scientists analysed blood and nasal swabs from a sample of 919 people living in the town of Gangelt in the western region of Heinsberg, where people were infected in February while visiting a carnival.

Dr Martin Exner, head of Bonn’s Institute for Hygiene and Public Health, who co-authored the study, said: “Apparently, one in five infections occurs without noticeable symptoms, suggesting that infected persons who secrete virus and can infect others cannot be reliably identified on the basis of recognisable symptoms of the disease."

+++++

I think we need to identify whether school age children form a high proportion of these
'Trojan Horses', before UK schools re-open.

Just the sort of thing for which our lateral flow test would be most appropriate.

IMO Antonio is attempting to sell the extra capacity created by the shorter manufacturing time of the dPCR test kit.
From this I suspect that the time to make a dPCR test kit is considerably shorter than the kit on sale since Feb / March.
So the increase is not from 8Mil to 10 Mil kits per month, it could be >10 Mil / month. - JM2c

https://www.express.co.uk/news/world/1277976/Germany-coronavirus-news-covid-19-cases-study-update?int_source=traffic.outbrain&int_medium=traffic.outbrain&int_term=traffic.outbrain&int_content=traffic.outbrain&int_campaign=traffic.outbrain

Not sure if this Express article has been posted before.
From May 6th, it points to a large number of people in Germany who are unaware they are carrying / distributing
the Covid 19 virus, because they have no symptoms.

"The team from the University of Bonn said there was potential for huge amounts of carriers not to have displayed any symptoms but still pose an infection risk to others.

Their report comes as Germany prepares to ease its lockdown with museums, hairdressers, churches and more car factories beginning to reopen.

It found one in five of those who had been infected with coronavirus reported no symptoms.

The scientists analysed blood and nasal swabs from a sample of 919 people living in the town of Gangelt in the western region of Heinsberg, where people were infected in February while visiting a carnival.

Dr Martin Exner, head of Bonn’s Institute for Hygiene and Public Health, who co-authored the study, said: “Apparently, one in five infections occurs without noticeable symptoms, suggesting that infected persons who secrete virus and can infect others cannot be reliably identified on the basis of recognisable symptoms of the disease."

+++++

I think we need to identify whether school age children form are a high proportion of these 'Trojan Horses', before UK re-opens the schools.

Just the sort of thing for which our lateral flow test would be most appropriate.

sharehunter3 - Thanks for the reminder..
"The Company continues to increase its sales level into the US market and is evaluating potential options to further expand its presence in this important market."

We must be due an update on USA soon, we haven't heard anything on the subject of USA for a while.

Apologies if this has been posted before, but I haven't seen this item posted in this BB yet.
Article almost a year old.
https://wall-street.com/4-huge-biotech-breakthroughs-will-revolutionize-health-industry/

Silver, - were these comments aimed at advising American investors?
I don't think these comments are usual in UK RNS's, but may be necessary to stop the actions of Ambulance Chasers in USA.
Is there a way to establish what % of investors are American?
JM2c.

From Monday’s RNS:
Leeds, 11 May 2020 - Tissue Regenix Group (AIM:TRX) ("Tissue Regenix" or the "Group" or "Company"), a leading regenerative medicine company, is pleased to announce that it has entered a new strategic collaboration for white label manufacturing with a leading top 10 global healthcare company bringing to market a newly developed product line.
The manufacturing agreement follows collaboration between the R&D teams of both companies to develop a new product using one of the Group's proprietary technology platforms to address orthopaedic soft tissue repairs. Processing for the product has begun, and initial orders have been received. Over the next two years, it is expected that the product will make a material contribution to the Group's top line revenue growth. This new product line is complimentary to the other soft tissue products processed at the San Antonio facility, and due to operational efficiencies implemented, it is not expected that there will be any impact on the current processing levels of other product lines.
++++
No mention of patents.

https://www.amerisourcebergen.com/solutions-manufacturers/brand-and-specialty
Brand Speciality.
“We have decades of experience partnering with brand and speciality manufacturers to design tailored commercialization strategies that optimise uptake and performance across the product lifecycle.”

This seems a good fit with the kind of arrangement that is presented above.
Can’t find any info (yet) re AmerisourceBergen announcing new products.

I have had a look at a few other of the ‘top 10’, but AmerisourceBergen seems best fit (so far) to the kind of white label activity being discussed in the RNS.

Hope you all have your spades and pickaxes out lads, there has to be one or two similar prospects...

From todays RNS:
"Large pharmaceutical companies, such as AstraZeneca and GSK, are now starting programmes to develop neutralising antibodies in an attempt to block the SARS-COV-2 spike protein's interaction with ACE2. Avacta has now demonstrated that several Affimer reagents also perform this blocking function and the Company is now seeking a partner that has the resources available to develop a neutralising Affimer therapy as quickly as possible."

If Astra and GSK are starting antibody based programmes, - and Avacta is advising of Affimer success in blocking interaction with ACE2 receptors, I think Alistair Smith is now advising the market of Avacta's success with Affimers, because he wants to know if there is a mega pharma out their who can prove itself to be a better partner than Astra or GSK.

The rights to any anti-virus development will belong to Avacta as it will be Affimer based.

JM2c on the reason for RNS release.

It was always evident that their were two bad news skeletons in the Novacyt cupboard, that would spoil the party.
1 19.02.2020 RNS - 67,67,567 shares in issue after Final Warrant Exercise and Issue of Equity.
(increase in number of shares in issue to eradicate the warrants).
Note: All outstanding warrants were exercised providing cash of €2,400,000 which has been used to expand manufacturing capacity for COVID-19, so it wasn't all bad.
2 Wait until mid May to announce the poor Final Results for the year ended 31 December 2019.

The cupboard is now empty of skeletons, but it's a shame the market had a bad day when the report was published.

We now know that "as of the end of April 2020, the Group had a net cash balance of €9.2m (cash as at 31 December 2019 of €1.8m)." Future end of month cash balances will be accruing at a much faster rate now that we know 10 million tests per month will be available after June.

Posts today have not dealt with the below RNS content, but these items will surely contribute further to the increasing monthly cash balances I expect to see.

"During the year, Primerdesign also completed the design and development of the molecular respiratory panel based on a 384 well plate format for use by its North American business partner in their CLIA approved diagnostic testing laboratory network. Primerdesign designed the multiplex test to identify 37 respiratory pathogens, which makes it one of the most comprehensive respiratory panels available in the market today. In addition to identifying a large number of respiratory disease pathogens, the new diagnostic product was designed with proprietary freeze-drying technology to stabilise the product to optimise its ease of use and performance.
Primerdesign will supply this product under a five-year manufacturing agreement as its partner launches the new respiratory panel in the US market through its own clinical testing laboratories to provide a Laboratory Developed Diagnostic Test ("LDT") result for its customers."

We need to know a lot more about the calculated number of test kits required for use with this instrument, how many instruments are contracted, what what will be the turnover from selling kits for this process, and the 'start work' date after commissioning. (2020 or beyond?)

The RNS also contained:
"The Company is already experiencing increased demand for its B2B molecular design and development capabilities and the Board believes these opportunities will extend to Novacyt's extensive product portfolio."
I expect profits to grow exponentially after delivering the C19 qPCR test so fast and so well that WHO sanctioned the test.

Seadoc - margins will come down and it will become essentially a commodity product.

It helps considerably if you are the first to market, or the best.

This was posted earlier:
https://www.linkedin.com/company/primerdesign/
As long as we are at the top of the league table on the 'Specificity report and independent clinical performance evaluation', (page 2) we can expect more and more B2B business enquiries.

We must expect in future competitors 'have you got it' (Antigen) tests to be more accurate.
At present they are making it easy for us to be head and shoulders the best choice.

We need more details on the following news, - like
a) how many pathogens tested all together or are pathogens tested serially, & speed of testing?
b) what test kit sales are forecasted for this instrument?
c) the first FDA cleared host response test for suspected sepsis patients, - more details required

During the year, Primerdesign also completed the design and development of the molecular respiratory panel based on a 384 well plate format for use by its North American business partner in their CLIA approved diagnostic testing laboratory network. Primerdesign designed the multiplex test to identify 37 respiratory pathogens, which makes it one of the most comprehensive respiratory panels available in the market today. In addition to identifying a large number of respiratory disease pathogens, the new diagnostic product was designed with proprietary freeze-drying technology to stabilise the product to optimise its ease of use and performance.

Primerdesign will supply this product under a five-year manufacturing agreement as its partner launches the new respiratory panel in the US market through its own clinical testing laboratories to provide a Laboratory Developed Diagnostic Test ("LDT") result for its customers.

The global respiratory disease testing market was valued in 2016 at US$5.0 billion1 and is forecast to grow at a rate of 3.3% per annum. The US market accounts for more than 30% of the global respiratory testing market.

1 Respiratory Disease Testing/diagnostics market, Industry Report, 2025 Grand View Rese


This development marked a significant step forward in the Group's B2B strategy by providing our North American business partner with the opportunity to serve the significant demand for the US seasonal respiratory testing market, which typically runs from September to April. It also demonstrated the increasing capability of Novacyt's R&D team as it broadens its product portfolio and builds the skills to develop more complex products. The rapid development of this new multiplex molecular diagnostic panel shows the power of our integrated research, development and commercialisation team.

In addition, during the year, Primerdesign expanded its assay development contract with Immunexpress, Inc., a U.S.-based molecular diagnostic company, with the first FDA cleared host response test for suspected sepsis patients. This is to further support the development of rapid diagnostic assays for the detection of sepsis. Sepsis is a potentially life-threatening complication in which a person's immune system inappropriately responds to an infection by triggering a broader inflammatory response, which could cause damage to multiple organs and ultimately lead to death. Left undiagnosed or untreated, a patient could die within a matter of hours. This contract expansion adds further momentum to our B2B segment and provides further validation of the expertise our clinical assay development service offers.

Will the dPCR kit cost more to buy because of its increased speed, (it costs less to produce)?
I'm not sure I've seen this discussed anywhere.

If so that is an even larger EBITDA.

Primerdesign operates on a payment with order basis, so no cash flow issues.

Care home in June , airports , football stadiums going forward would be nice ......

How about the Amazon jungle.....

https://www.youtube.com/watch?v=M9F1ZWxlehc

q16 instrument combined with the speed of dPCR is a very good combination.

What some people are missing here is that our aim is to manufacture 10 Million tests per month from June.
If there is a significant reduction in the processing time of the dPCR test,
then there will be a consequent greater demand for tests.
If a laboratory is flat out, and starts using dPCR tests, their daily capacity will increase due to shorter processing time.
Hence the extra testing availability and consequent increased demand for dPCR test kits.
Unless there is a fall in the number of tests in the queue, - but unfortunately nobody knows how big the second spike of diagnosis is going to be.

sharehunter3 - I agree.
"The Company is already experiencing increased demand for its B2B molecular design and development capabilities".
I think this will be the part of the business that is most profitable in future.
https://www.linkedin.com/company/primerdesign/
As long as we are at the top of the league table on the 'Specificity report and independent clinical performance evaluation', (page 2) we can expect more and more B2B business enquiries.

Ed,
So your thinking is SIPP's and ISAs will no longer be fire proof?

AshTrey,
I think we deserve significant 'post period' disclosure, but unsure whether we will get that much.

I find it significant that we were not given a specific day for the Annual Report publication, just in w/c 11 May 2020, so there could be something in what you say.